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ABSTRACT 
OBJECTIVE: The objective of this selective systematic review is to determine whether or not 
continuous subcutaneous hydrocortisone infusion (CSHI) therapy improves vitality in adult 
patients with Addison’s disease when compared to oral hydrocortisone therapy.  
STUDY DESIGN: This systematic review used three peer reviewed articles published in 
English. The articles were a crossover randomized control trial, a double bind placebo controlled 
clinical trial, and a case series published from 2007 to 2014.  
DATA SOURCES: The crossover randomized control trial and the double blind, placebo 
randomized control trial compared adult patients with Addison’s disease vitality scores when 
taking oral hydrocortisone tablets to continuous subcutaneous hydrocortisone infusion therapy. 
The case series followed 7 patients with Addison’s disease when taking continuous subcutaneous 
hydrocortisone infusion therapy and measured their vitality scores. The peer reviewed articles 
were found using PubMed and Google Scholar.  
OUTCOMES MEASURED: Vitality, the primary outcome, was measured by the Short Form-36 
Health Survey (SF-36). 
RESULTS: Data for all three articles was continuous and p-values were reported. The Lovas et 
al study reported a p-value of <0.05 and concluded that vitality scores are higher in patients with 
Addison’s disease taking CSHI therapy compared to their original therapy. The Gagliardi et al 
study and the Oksnes et al study report p values >0.05 suggesting that vitality scores comparing 
CSHI therapy to oral hydrocortisone therapy is not significantly different.   
CONCLUSIONS: The data is inconclusive in determining if continuous subcutaneous 
hydrocortisone therapy improves vitality in patients with Addison’s disease compared to oral 
hydrocortisone therapy.  
KEY WORDS: Addison’s disease, Continuous Subcutaneous Hydrocortisone Infusion Therapy, 
Oral Hydrocortisone, and Vitality.  
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INTRODUCTION  
Addison’s disease, also known as primary adrenal insufficiency, occurs when there is at 
least 90% damage to the adrenal glands leading to decreased production and secretion of 
hormones such as cortisol, aldosterone, and some sex hormones.1 Due to the diffuse role of 
adrenal hormones, patients present with constitutional symptoms such as weakness, fatigue, 
weight loss, and abdominal pain. Patients can also present with decreased sex drive, signs of 
decreased sex hormone production, and a craving for salt.2 The hallmark of the disease is 
hyperpigmentation in skin folds, pressure points, or in the mouth.3 Patients tend to be irritable 
and present with psychiatric illnesses, but the cause of this is unknown.3  
In the United States, eighty percent of patients with Addison’s disease are caused by an 
autoimmune process.2 Addison’s disease is rare; out of 1 million people in developed nations, 
110 to 144 patients have Addison’s disease.1 In the United States, it was reported that per 1 
million Americans, 40 to 60 have Addison’s disease.4 Although Addison’s disease is uncommon, 
patients can be treated at a primary care office, an endocrinology office, or in the ER if they 
present with a crisis. Considering the different specialists that attend to their care, national 
Addison’s disease healthcare costs amount to $2,320 per patient per year.5 In addition, to 
diagnose patients with the disease is about $1,680 dollars per patient.5 Considering the condition 
is rare, practitioners must have a high index of suspicion to limit unnecessary testing. The 
number of healthcare visits per year is not recorded, however, according to a Swedish study, 
patients with Addison’s disease have an increase in “all-cause mortality”.6 
 Typical treatments for Addison’s disease include oral hydrocortisone and sometimes 
dehydroepiandrosterone (DHEA)7. Currently, the gold standard treatment for patients with 
Addison’s disease is oral hydrocortisone tablets.2 However, patients with Addison’s disease that 
take oral hydrocortisone therapy have reported decreased quality of life which is theorized to be 
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due to noncircadian cortisol levels.7 In people with normal adrenal function, cortisol levels 
follow the light cycle and are at the highest waking and then decrease throughout the day 
reaching the lowest level at midnight.8 Cortisol levels trigger other biological clocks of the body, 
which also stresses the importance of obtaining normal endogenous cortisol levels.8 For patients 
with Addison’s disease, oral hydrocortisone therapy is typically 20 to 30 mg divided into three 
doses.7 Even though hydrocortisone is taken three times a day, the current dosing regimen of oral 
hydrocortisone does not mimic natural cortisol levels of the body.8  When cortisol levels are 
drawn, patients typically show extreme cortisol levels for that particular time of the day.7 
Continuous subcutaneous hydrocortisone infusion (CSHI) therapy, could theoretically restore 
cortisol’s circadian rhythm and improving vitality, or energy, in patients with Addison’s disease. 
Using two randomized control trials and one case series, this paper compares oral hydrocortisone 
therapy and continuous subcutaneous hydrocortisone infusion therapy in improving vitality in 
patients with Addison’s disease. 
OBJECTIVE  
 The objective of this selective systematic review is to determine if continuous 
subcutaneous hydrocortisone infusion therapy (CSHI) improves vitality in adult patients with 
Addison’s disease when compared to oral hydrocortisone therapy.  
METHODS 
 All studies used for this systematic review were researched by the author in English using 
PubMed and Google Scholar with specific key words such as: “Addison’s disease”, “Continuous 
Subcutaneous Hydrocortisone Infusion Therapy”, “Oral Hydrocortisone Therapy”, “Short Form-
36”, and “Vitality”. Criteria used to select studies was based on topic, patient characteristics, 
type of study conducted, and outcomes measured. Studies were considered if the subjects were 
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men and women with Addison’s disease and were over the age of 18. Studies were preferred if 
the interventions compared were oral hydrocortisone therapy and continuous subcutaneous 
hydrocortisone infusion therapy. The author searched for randomized control trials and case 
series only.  Articles were selected if they considered patient oriented outcomes (POEMS) that 
pertained to the clinical question and were published after 2006. Articles were excluded if they 
did not pertain to the clinical question, did not study the effects of continuous subcutaneous 
hydrocortisone infusion therapy, and did not study patients’ vitality scores before and after 
treatment. Articles that measured vitality using the short-form 36 were preferred to establish a 
control for the systematic review. The articles that fit the inclusion and exclusion criteria are 
discussed in this select systematic review.  Patient characteristics of the articles chosen are 
discussed in Table 1. Design and outcomes of each study are discussed in the result section of 
this systematic review.  
Table 1 - Demographics & Characteristics of included studies  
Study  Type  #Pts Age 
(yrs)  
Inclusion Criteria  Exclusion 
Criteria  
W/D Interventions 
Oksnes et al 
(2014)9  
 
Crossover 
Randomized 
Control Trial  
33 18-70 Pts diagnosed with 
Addison’s disease 
aged 18 to 70   
(-) DM, CVD, 
pregnancy, 
pharmacologic 
treatment with 
glucocorticoids 
or drugs that 
interfere with 
cortisol 
metabolism 
(antiepileptics, 
rifampicin, and 
St. Johns Wart)  
2 Continuous 
Subcutaneous 
Hydrocortisone 
Infusion 
Therapy   
 
Compared to  
 
Oral 
Hydrocortisone 
5 mg Tablets  
Gagliardi et 
al (2014)8 
Randomized 
Control Trial 
(Randomized, 
double blind, 
10  38- 62 “Endocrinologist-
certified diagnosis of 
autoimmune 
Addison’s disease”   
<18 years, 
bilateral 
adrenalectomy, 
secondary 
0 Continuous 
Subcutaneous 
Hydrocortisone 
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placebo 
controlled 
clinical trial)  
adrenal 
insufficiency, 
hypopituitarism, 
type 1 diabetes, 
celiac disease, 
pregnancy, 
disturbed sleep-
wake cycle, or 
current 
treatment for a 
major 
psychiatric 
disorder 
 
Infusion 
therapy  
 
Compared to  
 
Oral 
Hydrocortisone 
Lovas et al 
(2007)7  
Case Series 
(Open-
labelled 
feasible study)  
7 30- 64 
years 
of age  
“Biochemically 
verified Addison’s 
disease”  
None 0 Continuous 
Subcutaneous 
Hydrocortisone 
Infusion 
Therapy  
 
OUTCOMES MEASURED  
The three studies in this select systematic review discussed vitality pertaining to the 
administration of CSHI therapy. In all three articles, vitality was measured using Short Form-36. 
Short Form-36, also known as Short Form 36 Health Survey, is a 36-question survey used for 
medical research.8 The survey has eight sections: physical functioning, emotional role 
functioning, social role functioning, and mental health.8 Scores range from 0 to 100; higher 
scores indicate high function.8    
RESULTS 
Two randomized control trials and one case series are discussed in this systematic review. 
All studies obtained vitality scores from patients after the administration of CSHI therapy. Data 
from all three studies were continuous data, so p values and mean change from baseline were 
reported.  
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 In the randomized crossover study conducted by Oksnes et al. 33 patients with Addison’s 
disease aged 18 to 70 participated in a study comparing CSHI therapy to oral hydrocortisone 
therapy. Patients were randomly selected to take either continuous subcutaneous hydrocortisone 
therapy or oral hydrocortisone therapy. All patients involved in the study took both regimens by 
the completion of the study. Initially, day 0, patients were dose adjusted for both CSHI and oral 
hydrocortisone therapy. Oral hydrocortisone therapy was weight adjusted using 5 mg oral 
hydrocortisone tablets, and was taken 3 times a day during the trial. CSHI therapy was given at 
an infusion rate that was standard for all participants “8:00AM to 2:00 PM, 5 mg/ m^2; 2:00-
8:00 PM, 0.2 mg/m^2*h; 8:00 PM to 2:00 AM 0.05mg/m^2*h; and 2:00-8:00 AM, 1.0 
mg/m^2”.9 After three to five days, the CSHI therapy was dose adjusted based on salivary serum 
cortisol levels and serum cortisol levels in the morning.9 After dose adjustment, patients had a 
washout period of at least 1 month. During washout periods, patients would take pre-trial 
medications for their disease. After the first washout period, patients would either be randomly 
assigned CSHI therapy or oral hydrocortisone tablets for the first 12 weeks.9 Then, patients had a 
washout period of a minimum of 2 months. After the two months, patients would either take 
CSHI therapy or oral hydrocortisone therapy, whichever treatment was not administered to them 
during the first 12-week treatment period. The CSHI therapy was administered by an insulin 
pump; patients cleaned injection site prior to injection.9 Patients changed the infusion gear and 
hydrocortisone every three days. Two patients were withdrawn from the study by the 
researchers; one became pregnant during the trial and the other patient would not follow the 
guidelines set by the researchers.9 At each visit, patients completed the Short Form 36.   
The observed mean value of vitality scores when taking oral hydrocortisone therapy for 
12 weeks was 53.6, whereas, the mean value of vitality scores after 12 weeks of therapy with 
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CSHI therapy was 58.8.9 The predicted mean difference was 4.35 between the oral 
hydrocortisone therapy and CSHI at 12 weeks of therapy.9 Vitality scores in patients after 12 
weeks of therapy with CSHI therapy was greater than oral hydrocortisone therapy.9 The 
difference was not significantly different, but vitality scores were higher for CSHI therapy than 
oral hydrocortisone therapy.   
Table 2: The Observed Mean Value in Vitality Scores at 12 Weeks of Treatment 
 
 
In the randomized placebo control trial conducted by Gagliardi et al. ten patients with 
verifiable Addison’s disease participated in a trial of CSHI therapy and oral hydrocortisone 
therapy. The pharmacy department randomized the patients to treatment groups and also 
prepared the hydrocortisone and placebo capsules. Oral hydrocortisone therapy was given three 
times a day and was dose adjusted according to the patient’s usual treatment.8 The infusion 
consisted of hydrocortisone sodium succinate diluted in water to a concentration of 50 mg/mL, 
and the placebo infusion was normal saline.8 By the completion of the study, all patients had 
taken both treatments, CSHI therapy and oral hydrocortisone therapy. The treatment timeframe 
was 4 weeks followed by a two-week wash-out period. During treatment period, patients either 
received oral placebo with CSHI therapy or patients had oral hydrocortisone therapy with 
Author Oral 
Hydrocortisone 
 
CSHI 
therapy 
 
Predicted 
Mean 
Difference 
P for 
interaction 
Oksnes 
(2014)9 
 
53.6 (44.5, 62.7) 58.8 (49.4, 
67.7) 
4.53 (-2.1, 
11.1) 
0.177 
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subcutaneous placebo. No patients withdrew while the study was being performed. The Short 
Form-36 was completed prior to starting treatment and at the end of treatment.  
 The authors reported a mean change from baseline to compare the vitality scores of oral 
hydrocortisone therapy and CSHI therapy. There was an average increase of 10 on vitality scores 
when comparing CSHI vitality scores from baseline to the end of treatment.8 There was a 
decrease in vitality scores by 2 in the oral hydrocortisone treatment group when comparing 
baseline scores to end of treatment.8 The exact p-value was not reported, but the authors noted 
that the p-value for vitality scores was greater than 0.05 and was not considered statistically 
significant.8 However, vitality scores of CSHI therapy trend higher than oral hydrocortisone 
levels overall.  
Table 3: The Mean Change in Vitality Scores Before and After Treatment 
Author Oral 
Hydrocortisone 
CSHI therapy 
 
Mean 
Difference 
p-value 
Gagliardi (2014)8 -2 10 12 >0.05 
 
In the case series conducted by Lovas et al. seven patients with Addison’s disease 
participated in a study to determine the efficacy of CSHI and patients’ satisfaction with 
treatment. Initially, one patient was in a three-month trial to determine the dosage of 
hydrocortisone for the infusion therapy. The second patient was used to determine the affects of 
the HTA axis by measuring cortisol in serum and saliva.7 Then, five patients with Addison’s 
disease participated in an open-labeled two-week trial of using CSHI therapy for their Addison’s 
disease treatment. If patients were satisfied with the treatment, they had the option to extend their 
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trial by 10 weeks.7 The CSHI therapy was given by using an insulin pump and was inserted into 
the abdominal wall subcutaneously. The insulin pump was changed every three days as well as 
the 50mg/mL solution of hydrocortisone therapy.7 Each patients cortisol therapy was measured 
by salivary cortisol levels on two consecutive days at the beginning of the two weeks and two 
consecutive days at the end of the two weeks.7 If patients decided to continue the trial past the 
two weeks, cortisol levels were measured on an as needed basis. Patients completed the Short 
Form-36 at each visit.  
The changes from baseline were analyzed by using a paired t test and clinical significance 
was considered <0.05.7 If patients chose not to participate after 2 weeks, their data was also used 
for statistical analysis. Only one participant decided to stop treatment after the two weeks.7 The 
patient was satisfied with the treatment, but decided to revert back to their original treatment.  At 
the conclusion of the experiment, patients were satisfied overall with the CSHI therapy. Two 
patients decided to be treated with CSHI treatment long term for their Addison’s disease.7 
Patients vitality scores were significantly different when comparing scores before and after CSHI 
therapy. There was an average increase in CSHI therapy vitality scores by 23 from baseline to 
the end of treatment.7 This value is large considering the type of study. The researchers did not 
report the exact p-value, but noted the p value for vitality scores was <0.05.7  
Table 4: Baseline and After CSHI therapy Mean Vitality Scores  
Author Baseline   End of 
Treatment 
Mean 
Difference 
P value 
Lovas (2007)7 30 53 23 <0.05 
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DISCUSSION  
Although Addison’s disease is rare, patients report decreased quality of life with the gold 
standard therapy, oral hydrocortisone tablets.7 The current guideline for treatment is oral 
hydrocortisone tablets 15 to 25 mg divided into two to three doses a day.10 Patients are instructed 
to take the morning dose as soon as they wake for the day. The second dose should be either with 
lunch or two hours after lunch. Lastly, the third dose should be administered no later than 4 to 6 
PM.10 The morning dose is the highest, and the evening dose is the lowest.10 There is currently 
no black box warning for oral hydrocortisone therapy. Oral hydrocortisone is currently used in 
almost all medical specialties for various diseases.  Patients with normal adrenal function should 
be advised about potential hydrocortisone withdrawal. Patients may experience GI upset, 
dizziness, mood changes, or muscle weakness.10 Hydrocortisone withdraw can be avoided with a 
slow taper to allow the adrenal glands to resume its normal function.  
Currently, the FDA notes that IM and IV preparations of hydrocortisone can be used for 
treatment of various conditions, if oral hydrocortisone therapy is not possible.11 However, the 
FDA does not mention approval of the use of continuous subcutaneous hydrocortisone infusion 
therapy in patients with Addison’s disease. Numerous studies have explored the benefits of 
subcutaneous hydrocortisone therapy in the treatment of Addison’s disease and in emergency 
adrenal crisis situations. 
 The three studies discussed in this systematic review study the use of CSHI therapy as an 
alternative treatment for patients with Addison’s disease. All articles, except for the study 
conducted by Oksnes et al, had few participants in their studies which may have decreased the 
validity of the results. The case series, study conducted by Lovas et al, only looked at vitality 
scores of patients who were using CSHI therapy and did not compare vitality scores of oral 
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hydrocortisone therapy. The case series compared vitality scores before and after treatment, but 
most patients were not taking oral hydrocortisone therapy prior to CSHI therapy. Patients were 
also aware of the treatment they were receiving in the case series. The Gagliardi et al study had a 
short wash-out period of 2 weeks whereas the study conducted by Oksnes et al had a washout 
period of at least 1 month. Although these studies had limitations, they still shed light on 
patients’ vitality while using CSHI therapy. 
CONCLUSION  
 The data is inconclusive in determining whether CSHI therapy improves vitality scores in 
patients with Addison’s disease when compared to vitality scores of patients using oral 
hydrocortisone therapy. The studies conducted by Gagliardi et al and Oksnes et al concluded that 
the mean change in vitality scores were not significantly different when comparing CSHI therapy 
and oral hydrocortisone therapy. Even though the mean changes were not significantly different, 
both studies showed higher vitality scores in patients that were taking CSHI therapy when 
compared to oral hydrocortisone therapy. Although the study performed by Lovas et al did not 
compare CSHI to oral hydrocortisone therapy, the study concluded that the vitality scores were 
significantly different when comparing the patients’ traditional therapy to CSHI therapy. It 
seems that CSHI therapy improves vitality somewhat, but the data is conflicting.  
 More studies need to be done comparing vitality scores of patients taking CSHI therapy 
and oral hydrocortisone therapy. The gold standard therapy, oral hydrocortisone tablets, does not 
mimic the body’s normal circadian rhythm of cortisol which may greatly impact patient’s 
vitality. Studies with less patient exclusion criteria should be considered, so more patients are 
able to participate in future studies. With very few treatments available for patients with 
Addison’s disease, another alternative therapy would greatly impact their lives. 
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